Safety and Efficacy of Bimatoprost 0.03% Solution for the Treatment of Thinning Eyebrows
Completed · Phase 4 · Has a placebo group
Conditions studied: Hypotrichosis
In brief
This is a study researching the safety and efficacy of Bimatoprost 0.03% soultion versus placebo applied to the eyebrow for the treatment of thinning eyebrows. This is a 36 week study where Bimatoprost 0.03% solution/placebo will be applied once daily to the subjects eyebrow for duration of the study.
Key facts
- Study ID
- NCT01891487
- Run by
- ATS Clinical Research
- People needed
- 33
- Starts
- 2013-05-01
- Expected to finish
- 2015-01-01
- Last updated by the study team
- 2015-01-14
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- Females and males, ages 18-75 years with brows that are naturally thinning with a score of 1 (very thin) or 2 (thin) at baseline as determined by the Investigator Global Eyebrow Assessment (IGEA).
- Subjects who agree to forgo any additional treatment to the brows, such as waxing, plucking, threading and/or tinting for the duration of the study.
- Desires to participate in a research study
You may not qualify if…
- Any uncontrolled systemic disease.
- Any known diseases or abnormalities to the eyelid or eyebrow.
- Known allergies or reactions to bimatoprost or placebo ingredients.
- Pregnancy.
- Subjects that have thinning brows as a result of over plucking, trichotillomania, chemotherapy or any other condition or treatment that causes hair loss.
- Subjects who have used any over the counter or prescription eyebrow growth product 3 months prior to baseline.
- Subjects with tattooed eyebrows and/or any permanent or semi-permanent tint or dye within 3 months prior to baseline.
- Subjects with a score of 3 or 4 on the eyebrow scale.
- Current enrollment in an investigational drug or device study or participation in such a study 30 days prior to baseline.
- Subjects using prostaglandin analogs for the treatment of high intraocular pressure.
- Aphakic subjects and/or pseudophakic subjects with a torn posterior lens capsule.
- Subjects with known risk factors for macular edema.
Where it is running
- Ava MD — Santa Monica, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.